+ +

•  

   

     Result: P15285 can detect human IL36G by Western blotting.    

  
  

Interleukin-36 gamma (IL-36γ), a pro-inflammatory cytokine belonging to the IL-1 family, plays a critical role in modulating innate and adaptive immune responses. Primarily expressed in epithelial tissues, IL-36γ binds to the IL-36 receptor (IL-36R) and activates downstream signaling pathways, including NF-κB and MAPK, to promote the release of inflammatory mediators. Dysregulated IL-36γ signaling is implicated in chronic inflammatory and autoimmune diseases, particularly psoriasis, where it drives keratinocyte hyperproliferation and immune cell infiltration.

IL-36γ-targeting antibodies have emerged as promising therapeutic agents to block pathological IL-36/IL-36R interactions. These antibodies are designed to neutralize IL-36γ activity, thereby suppressing excessive inflammation and tissue damage. Preclinical studies demonstrate their efficacy in reducing disease severity in psoriasis-like models and other IL-36-mediated conditions, such as generalized pustular psoriasis (GPP) and inflammatory bowel disease (IBD). Several anti-IL-36γ antibodies are currently in clinical trials, highlighting their potential as precision therapies for patients unresponsive to conventional treatments. By selectively inhibiting IL-36γ, these antibodies aim to achieve a favorable safety profile compared to broad immunosuppressants, addressing a significant unmet need in chronic inflammatory disease management.